Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma

Leuk Lymphoma. 2019 Feb;60(2):511-514. doi: 10.1080/10428194.2018.1473577. Epub 2019 Jan 8.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / methods
  • Humans
  • Lenalidomide / administration & dosage
  • Lenalidomide / adverse effects
  • Lenalidomide / therapeutic use*
  • Maintenance Chemotherapy
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / mortality*
  • Multiple Myeloma / therapy*
  • Postoperative Care*
  • Prognosis
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Lenalidomide